Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Total Liabilities & Equity

Total Liabilities & Equity at other companies

Gilead Sciences logo
Gilead SciencesGILD
$49.36B-11.4%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$442.32M+14.4%
LQD
Liquidia CorporationLQDA
$401.53M+76.6%
ALN
Alnylam PharmaceuticalsALNY
$5.56B+21.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.37B+55.5%
Arrowhead Research logo
Arrowhead ResearchARWR
$2.27B+44.2%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemJune 30,2026December 31,2025
Stockholders’ (deficit) equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 200,000,000 shares authorized; 64,754,699 and 51,896,391 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively65
Additional paid-in capital1,515,172981,878
Accumulated deficit(1,524,926)(667,544)
Accumulated other comprehensive (loss) income(674)351
Total stockholders’ (deficit) equity(10,422)314,690
Total liabilities and stockholders’ (deficit) equity$1,044,981$842,813

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s total liabilities & equity?
Mirum Pharmaceuticals, Inc. (MIRM) reported total liabilities & equity of $1.04B in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
Mirum Pharmaceuticals, Inc.'s total liabilities & equity increased by 44.0% year-over-year, from $725.83M to $1.04B.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Mirum Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 28.5% compound annual growth rate (CAGR), from $240.86M to $842.81M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Mirum Pharmaceuticals, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude